Ocugen, Inc.

OCGN | $1.585 -0.31% -0.32% 2.9M

(0.0% 1d) (54.4% 1m) (94.0% 1y) (0.0% 2d) (0.0% 3d) (-11.7% 7d) (-14.44% volume)
Earnings Calendar: 2024-04-16
Market Cap: $ 406,556,358
http://www.ocugen.com
Sec Filling | Patents | 16 employees

(US) Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

vaccine eye diseases eye

add to watch list Paper trade email alert is off

Precigen, Inc.

PGEN M | $1.36 -2.86% -2.94% 850K

Health Technology

(0.0% 1d) (0.7% 1m) (20.7% 1y) (0.0% 2d) (0.0% 3d) (-0.7% 7d) (31.22% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 338,529,971
http://www.precigen.com
Sec Filling | Patents | 857 employees

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

autoimmunity infectious disease glass food t-cell ceiling

add to watch list Paper trade email alert is off

Revolution Medicines, Inc.

RVMD S | $36.29 2.11% 2.07% 1.2M

Health Technology

(0.0% 1d) (14.9% 1m) (44.6% 1y) (0.0% 2d) (0.0% 3d) (-2.6% 7d) (-29.16% volume)
Earnings Calendar: 2024-02-26
Market Cap: $ 5,976,600,100
http://www.revmed.com
Sec Filling | Patents | 95 employees

(US) Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

cancer treatment cancer treatments

add to watch list Paper trade email alert is off

ICON plc

ICLR | $293.91 -1.74% -1.77% 650K

Health Technology

(0.0% 1d) (-10.0% 1m) (39.8% 1y) (0.0% 2d) (0.0% 3d) (-4.1% 7d) (-2.28% volume)
Earnings Calendar:
Market Cap: $ 24,246,130,726
http://www.iconplc.com
Sec Filling | Patents | 14650 employees

(IE) ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

msa

add to watch list Paper trade email alert is off

Checkpoint Therapeutics, Inc.

CKPT | $1.665 -3.2% -3.3% 510K

Health Technology

(0.0% 1d) (-8.5% 1m) (-32.7% 1y) (0.0% 2d) (0.0% 3d) (-2.8% 7d) (NaN% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 58,252,155
http://www.checkpointtx.com
Sec Filling | Patents | 8 employees

(US) Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.

acquisitions cancer treatment

add to watch list Paper trade email alert is off

Agilent Technologies, Inc.

A | $136.8 -2.44% 0.0% 1.3M

Health Technology

(0.0% 1d) (-4.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (33.93% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 40,089,962,851
http://www.agilent.com
Sec Filling | Patents | n/a employees

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

genomic urea diagnostics msa

Drugs

Hand Sanitizer (Isopropyl Alcohol)

add to watch list Paper trade email alert is off

Astellas Pharma Inc

ALPMF | $9.48 43.47% 1.7K

Health Technology

(0.0% 1d) (-16.2% 1m) (-37.2% 1y) (0.0% 2d) (-8.4% 3d) (-8.4% 7d) (-85.33% volume)
Earnings Calendar:
Market Cap: $ 17,155,605,951
http://www.astellas.com
Sec Filling | Patents | n/a employees

(JP) Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

brands infectious disease metabolic diabetic diabetes

add to watch list Paper trade email alert is off

KONINKLIJKE PHILIPS NV

RYLPF | $20.515 3.85% 7K

Health Technology

(0.0% 1d) (-0.9% 1m) (12.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (4418.83% volume)
Earnings Calendar:
Market Cap: $ 18,644,860,868
http://www.philips.com
Sec Filling | Patents | n/a employees

(NL) Royal Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The Personal Health segment focuses on healthy living and preventative care. This segment comprises the Personal Care, Domestic Appliances, Oral Healthcare, and Mother & Child Care businesses. The Diagnosis & Treatment segment unites the businesses related to the promise of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatments. This segment comprises the Diagnostic Imaging, Ultrasound, Healthcare Informatics and Image-Guided Therapy businesses. The Connected Care & Health Informatics segment focuses on patient care solutions, advanced analytics and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways and leveraging provider-payer-patient business models. This segment comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, and Sleep & Respiratory Care businesses. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

diagnostics respiratory treatment optical

add to watch list Paper trade email alert is off